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ABSTRACT 
Although neuroleptic malignant syndrome manifests consistently with hyperthermia, muscle 
rigidity, altered mental status, and autonomic instability, heterogeneity exists in the onset, course, 
laboratory findings, response to treatment and pattern of resolution. Comorbid physical conditions 
tend to confuse the picture. We report a case of NMS with one such presentation. 
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Neuroleptic malignant syndrome (NMS) 
is a rare serious complication of neuroleptic 
therapy (Addonizio and Susman, 1991). The 
criteria for diagnosing NMS have ranged from 
the rigid ones proposed by Levenson (1985) to 
the more flexible ones by Addonizio and 
Susman (1991), Caroff and Mann (1988) and 
to one of the most liberal suggested by 
DSM-IV (APA, 1994), where along with severe 
muscle rigidity, elevated temperature, two out 
of a combined list of 10 clinical features and 
investigative abnormalities, have to be present 
for a diagnosis of NMS. Other causes to 
account for the clinical picture have to be ruled 
out. 
Several risk factors have been proposed, 
which along with neuroleptic exposure, 
predisposes an individual to NMS. Besides 
supportive therapy and discontinuation of 
antipsychotics, successful treatment has been 
reported with drugs like Amantadine, 
Dantrolene sodium and Bromocriptine mesylate 
(Greb'e, 1995). 
There is however no consensus on the 
course and pattern of resolution of symptoms. 
CASE REPORT 
Miss U, a 32 year old unmarried lady was 
brought to this hospital with 3 days history of 
fever, poor self care, restlessness, and disori-
entation. 
For 2 months prior to above, patient was 
expressing sad mood, tearfulness, poor sleep 
and appetite. Around 30th day of her illness she 
was shown to a local psychiatrist, who 
prescribed her tab. haloperidol 5mg once a day, 
tab. alprazolam 0.25mg 1/2-0-1, tab. 
trihexiphenidyl 2mg twice daily. Patients appar-
ently did not show any improvement, and 4 days 
later was hospitalised, and the dose of haloperi-
dol increased. After a stay of 7 days in the hos-
pital, patients was discharged on tab. haloperi-
dol 5mg thrice daily,.tab. trihexiphenidyl 2 mg 
thrice daily and tab. alprazolam 0.25 mg 1/2 
tab. twice daily and 1tab in evening. 
Past history was suggestive of depres-
sive episodes, 10 and 15 years ago.Family his-
tory of depressive illness in younger brother. 
Premorbidly patient was scholastically 
backward. 
At admission, patient was febrile, BP140/ 
/100 mm Hg, pulse 98/min, regular, normal 
volume, cog wheel rigidity and tremors in the 
out stretched hands were present. Mental 
status examination showed poor attention span, 
disorientation and an anxious affect. 
Laboratory investigations : ESR, WBC 
total count, differential count, urine routine 
examinations, renal parameters, electrolytes, 
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and liver function tests were within normal 
limits. Blood smear for malarial parasites was 
negative. CPK was 2087 IU/L and LDH 489 
IU/L. 
Patient was started on tab. lorazepam 
1mg twice daily, on the day of admission and 
increased gradually up to 2 mg twice daily over 
the stay. Paracetamol was administered when-
ever required. The patient continued to be fe-
brile (temp 101 °F- 104°F). Rigidity assumed a 
lead pipe character and disorientation became 
prominent. Fluctuation in B.P., pulse, respira-
tory rate and increased sweating were observed. 
Patient was started on tab. bromocriptine 5mg 
1/2 twice daily, increased up to 5mg thrice daily 
over the course of illness. 
Autonomic instability, muscle rigidity and 
higher mental functions showed remarkable 
improvement after 5-6 days of bromocriptine 
therapy, but she continued to be febrile. CPK 
levels dropped to 1161 IU/L after 3 days and to 
70 IU/L after 11 days of starting bromocriptine. 
A medical consultation was sought on the 
10th day as the fever continued to be high. 
Despite repeated blood smear examination 
being negative, an empirical trial of 
pyrimethamine and sulphadoxine was given. 
Fever persisted. Blood culture, urine culture and 
widal test did not reveal any abnormalities. 
Ciprofloxacin was started empirically, and 
within 3 days the patient became afebrile. 
Patient was afebrile, had no muscle rigidity or 
tremors at the time of discharge. 
DISCUSSION 
Several criteria have been proposed for 
NMS (Levenson, 1985; Addonizio and Susman, 
1991; DSM-IV, 1994).Our patient who had 
confusion, severe rigidity, autonomic 
instability, raised CPK and with a history of 
neuroleptic exposure would definitely be 
considered one of them. Over and above, the 
patient had a few factors for developing 
NMS,viz. exposure to haloperidol -a high 
potency neuroleptic (Caroff, 1980), a recent hike 
of the same, affective disorder, mental 
retardation (Alexander et al., 1996). 
Was the course of illness in this case 
typical of NMS? Although a potentially lethal 
condition, resolution of symptoms of NMS in 
cases untreated with dopaminergic agonists or 
dantrolene is not completely unknown. The 
mean recovery time in 65 cases, according to 
Caroff and Mann (1988) was 9.6+9.1 days. 
Although bromocriptine has been reported to 
reduce the symptoms of NMS within 6 hours of 
first dose (Dhib-Jhalbut et al., 1985; Zubenko 
and Pope, 1983), in the 14 cases of NMS 
reported by Itoh et al. (1977) fever lasted 4-17 
days and rigidity persisted for several weeks 
after patients had become afebrile. On the other 
hand , a discrepancy between temperature 
course and CPK level has also been reported 
(Dhib-Jalbut et al. 1987). The exact pattern of 
symptom resolution in NMS with bromocriptine 
is unknown and therefore this case is not all 
that unusual. No acute or chronic physical 
conditions to account for the fever could be 
detected by the physician. A therapeutic trial of 
pyrimethamine + sulphadoxine proved 
unsuccessful. Though the therapeutic trial of 
ciprofloxacin was seemingly successful, one 
should keep in mind that NMS has its own 
course and is known to remit without treatment 
also. 
We propose that there should be no stone 
unturned in the quest for a comorbid condition 
alongside NMS and that systematic reports be 
made available regarding symptom resolution 
in NMS with various treatment modalities for 
better management. 
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